SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

rezatapopt

PMVP·PMV Pharmaceuticals, Inc.
BULLISH
Drug Impact Rating8/10
Trial phase
Phase 2 (pivotal)
Time to market
NDA submission planned for Q1 2027 under accelerated approval pathway. If accepted and approved under standard review timelines, potential FDA decision could come in late 2027 or early 2028.
Why 8/10
The next hard, dated catalyst is the late-breaking oral presentation of updated pivotal Phase 2 PYNNACLE data at the ENA 2026 symposium on November 20, 2026 (roughly 9 days from today). Rezatapopt is PMVP's only clinical-stage asset and drives essentially the entire company valuation, making this a high-impact event. The NDA submission planned for Q1 2027 is the subsequent major binary.
Actionable Insight BULLISH

The next catalyst is the late-breaking oral presentation of updated PYNNACLE Phase 2 data at ENA 2026 on November 20, 2026, roughly 9 days away. Positive data could reinforce the NDA submission narrative and support the stock, while disappointing results (weaker efficacy or safety signals) could undermine the accelerated approval path. The NDA submission itself, planned for Q1 2027, is the next major binary event after ENA.

Price Chart

Loading chart...

Executive Summary

Rezatapopt (PC14586) is PMV Pharmaceuticals' lead and only clinical-stage asset, a first-in-class oral small molecule that reactivates the mutant p53 Y220C tumor suppressor protein found in about 1% of solid tumors. In August 2026, the company reported a 46% overall response rate with a 10-month median duration of response in 76 evaluable platinum-resistant/refractory ovarian cancer patients from the pivotal Phase 2 PYNNACLE trial. The FDA granted Fast Track and Orphan Drug designations in October 2026. The company plans to submit an NDA for accelerated approval in Q1 2027. The next catalyst is a late-breaking oral presentation of updated PYNNACLE data at the ENA 2026 symposium on November 20, 2026. PMVP trades at $1.26 with a strong buy analyst consensus and a mean price target of $4, implying roughly 228% upside.

How It Works

Rezatapopt is an oral small molecule designed to fix a broken tumor-suppressor protein called p53. In about 1% of solid tumors, a specific mutation (Y220C) creates a small pocket in the p53 protein that causes it to misfold and stop working. Rezatapopt fits into that pocket like a key, stabilizing the protein and restoring its ability to suppress tumor growth. It is taken as a pill and targets only cancer cells carrying this specific mutation.

Trial Status

The pivotal Phase 2 PYNNACLE trial (NCT04585750) is evaluating rezatapopt monotherapy in patients with TP53 Y220C-mutated advanced solid tumors. The ovarian cancer cohort has reported a 46% ORR among 76 evaluable patients with a median duration of response of 10.0 months. Updated data across tumor types will be presented as a late-breaking oral presentation at ENA 2026 on November 20, 2026.

The Two-Sided Case

▲ Bull Case5
Rezatapopt is a first-in-class oral p53 Y220C reactivator addressing a high-unmet-need population with no approved targeted therapy for this mutation.
Phase 2 PYNNACLE data showed a 46% overall response rate with a 10-month median duration of response in 76 evaluable platinum-resistant/refractory ovarian cancer patients, a heavily pretreated population.
FDA granted both Fast Track and Orphan Drug designations in October 2026, signaling regulatory support and potential for expedited review.
The company plans to submit an NDA for accelerated approval in Q1 2027, and recent FDA interactions support this path.
Analyst consensus is strongly bullish: 10 analysts rate it Buy/Strong Buy with a mean price target of $4 (227.9% upside from the $1.22 reference price).
▼ Bear Case5
Rezatapopt is PMVP's only clinical-stage asset; any clinical setback or regulatory delay would leave the company with no pipeline and limited value.
The company reported a net loss of $34.37M in Q3 2026 alone, and while it raised $50M in an oversubscribed offering, the cash burn rate is high for a micro-cap stock trading at $1.26.
Multiple institutional holders (Morgan Stanley, Jane Street, RBC) significantly trimmed or nearly exited their positions in Q2 2026, signaling caution from sophisticated investors.
The target population (TP53 Y220C mutation) is narrow, found in only about 1% of solid tumors, limiting the total addressable market even if approved.
Resistance mechanisms to p53-targeted therapy have been documented, which could limit the drug's durability of response.

Upcoming Catalysts

  • Late-breaking oral presentation of updated PYNNACLE Phase 2 data at ENA 2026 (38th EORTC-NCI-AACR Symposium) on November 20, 2026
  • NDA submission for accelerated approval in platinum-resistant/refractory ovarian cancer planned for Q1 2027
  • Potential FDA acceptance of NDA and priority review designation in 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PMV Pharmaceuticals, Inc. 8-K PMVP ·Originating report

Sources · 11

Hover a chip for the title
1 markets.businessinsider.com2 markets.businessinsider.com3 msn.com4 streetinsider.com5 wboc.com6 seekingalpha.com7 medicalxpress.com8 bioworld.com9 marketscreener.com10 msn.com11 cancernetwork.com